Patents by Inventor Stephen Willingham

Stephen Willingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190218289
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 18, 2019
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • Patent number: 10344094
    Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 9, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer
  • Patent number: 10301387
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 28, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • Publication number: 20190076433
    Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A) receptor antagonist and a programmed cell death protein 1(PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2Areceptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.
    Type: Application
    Filed: December 22, 2016
    Publication date: March 14, 2019
    Inventors: Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian McCaffery, Andrew Hotson
  • Publication number: 20190022096
    Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A (A2A) receptor antagonist, or a combination of an adenosine-A2A (A2A) receptor antagonist, CTLA4 antagonist a programmed cell death protein 1 (PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a CTLA4 antagonist and a PD-1 signaling pathway inhibitor, and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: April 4, 2018
    Publication date: January 24, 2019
    Inventors: Stephen Willingham, Ian McCaffery
  • Publication number: 20180353582
    Abstract: Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.
    Type: Application
    Filed: July 30, 2018
    Publication date: December 13, 2018
    Inventors: Diane Tseng, Jens-Peter Volkmer, Kipp Andrew Weiskopf, Stephen Willingham, Irving L. Weissman
  • Patent number: 10064925
    Abstract: Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: September 4, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Diane Tseng, Jens-Peter Volkmer, Kipp Andrew Weiskopf, Stephen Willingham, Irving L. Weissman
  • Publication number: 20170210803
    Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 27, 2017
    Inventors: Stephen Willingham, Doris Po Yi Ho, Kelly Marie McKenna, Irving L. Weissman, Jens-Peter Volkmer, Mark P. Chao, Ravindra Majeti, Melissa N. McCracken
  • Publication number: 20170166645
    Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Application
    Filed: December 8, 2016
    Publication date: June 15, 2017
    Inventors: Irving L. Weissman, Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer
  • Publication number: 20170145096
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Application
    Filed: February 2, 2017
    Publication date: May 25, 2017
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • Patent number: 9623079
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: April 18, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • Publication number: 20160144009
    Abstract: Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.
    Type: Application
    Filed: April 23, 2014
    Publication date: May 26, 2016
    Inventors: Diane Tseng, Jens-Peter Volkmer, Kipp Andrew Weiskopf, Stephen Willingham, Irving L. Weissman
  • Publication number: 20160008429
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Application
    Filed: February 26, 2014
    Publication date: January 14, 2016
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman